IV
Philadelphia, PA, United States
IV
Philadelphia, PA, United States

Time filter

Source Type

The International Nurses Association is pleased to welcome Shaun Marie Sever, RN, BSN, MACJ, ALNC to their prestigious organization with her upcoming publication in the Worldwide Leaders in Healthcare. Shaun Marie Sever is a Legal Nurse Consultant with 21 years of experience in her field and an extensive expertise in all facets of nursing, especially home infusion, emergency department, and critical care nursing. Shaun is currently serving patients as a Home IV Infusion RN within Dohmen Life Science Services, as RN Manager of Okemos Infusion Suite within Okemos Allergy Center, and is a former Emergency Room Nurse. Furthermore, she is the founder and owner of SPLNC & Associates LLC, a Legal Nurse Consulting firm in Eaton Rapids, Michigan. Shaun Marie Sever obtained her Associate’s Degree in Nursing in 1996 from Lansing Community College. An advocate for continuing education, she went on to gain her Bachelor of Science Degree in Nursing in 2011 from Jacksonville University, before attending Keiser University, where she graduated with her Master of Arts Degree in Criminal Justice in 2014. Shaun is certified in Basic Life Support, Advanced Cardiac Life Support, Pediatric Advanced Life Support, Trauma Nursing Core Course, Emergency Nursing Pediatric Course, and obtained certification as an Advanced Legal Nurse Consultant in 2014. As a Legal Nurse Consultant and owner of SPLNC & Associates LLC, Shaun interprets patient charting and can recognize errors in records as well as omissions. To keep up to date with the latest advances in her field, she maintains a professional membership with the American Nurses Association and the Michigan Nurses Association. Furthermore, Shaun is a retired Sergeant First Class in the United States Army with 20 years of service and an honorable discharge. She calls upon her experience in the US Army to provide consulting services with honesty, integrity, and loyalty. She attributes her success to her hard work and dedication, and when she is not working, Shaun enjoys football, basketball, walking, and fishing. Learn more about Shaun Marie Sever here: http://inanurse.org/network/index.php?do=/4135371/info/ and http://www.splegalnurse.com/ and be sure to read her upcoming publication in the Worldwide Leaders in Healthcare.


News Article | February 27, 2017
Site: globenewswire.com

MIAMI, Feb. 27, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the fourth quarter ended December 31, 2016 after the close of the U.S. financial markets on Wednesday, March 1, 2017. OPKO’s senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Wednesday, March 1, 2017. For those unable to participate in the live conference call or webcast, a replay will be available beginning March 1, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 80392791. The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com/events.cfm. About OPKO Health, Inc. OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com.


RALEIGH, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA” or the “Company”) (NASDAQ:PRAH) today reported financial results for the quarter ended December 31, 2016. For the three months ended December 31, 2016, service revenue was $413.6 million, which represents growth of 14.2%, or $51.3 million, compared to the fourth quarter of 2015 at actual foreign exchange rates. On a constant currency basis, service revenue grew $52.9 million, an increase of 14.6% compared to the fourth quarter of 2015. Net new business for the quarter ended December 31, 2016 was $587.3 million, representing a net book-to-bill ratio of 1.42 for the period. This net new business contributed to an ending backlog of $2.9 billion at December 31, 2016. “We are pleased to have delivered another quarter with double-digit revenue, earnings and net new business growth year-over-year,” said Colin Shannon, PRA’s Chief Executive Officer. “We are well-positioned to deliver at least mid-teens growth during the coming year, as evidenced by our record level of new business awards and backlog. We continue to stay focused on our key strategic objectives, our client deliverables and developing our people, and we look forward to delivering strong results in 2017.” Direct costs were $274.4 million during the three months ended December 31, 2016 compared to $234.9 million for the fourth quarter of 2015. Direct costs were 66.3% of service revenue during the fourth quarter of 2016 compared to 64.8% of service revenue during the fourth quarter of 2015. The increase in direct costs as a percentage of service revenue is due to the continued hiring of billable staff to support our current projects and the hiring of additional staff to ensure appropriate staffing levels to support our future growth. Selling, general and administrative expenses were $70.2 million during the three months ended December 31, 2016 compared to $63.6 million for the fourth quarter of 2015. Selling, general and administrative costs were 17.0% of service revenue during the fourth quarter of 2016 compared to 17.6% of service revenue during the fourth quarter of 2015. The decrease in selling, general and administrative expenses as a percentage of revenue is attributable to our ability to continue to effectively manage our sales and administrative functions as the Company continues to grow. For the three months ended December 31, 2016, we incurred transaction-related expenses of $13.0 million. The costs consist of $12.7 million of one-time stock-based compensation expense related to the release of transfer restrictions on vested options and the vesting of certain performance-based stock options in connection with the November secondary offering. In addition, we incurred $0.3 million of third-party fees associated with the secondary offering. During the fourth quarter of 2016, we also incurred a loss on extinguishment of debt of $16.7 million. This loss is associated with our refinancing on our first lien term debt, which included the write-off of $15.8 million of unamortized debt issuance costs and $0.9 million of other costs associated with the transaction. GAAP net income was $14.0 million for the three months ended December 31, 2016, or $0.22 per share on a diluted basis, compared to GAAP net income of $28.5 million for the three months ended December 31, 2015, or $0.45 per share on a diluted basis. Our GAAP net income for the three months ended December 31, 2016 included transaction-related expenses and the loss on extinguishment discussed above. EBITDA was $54.3 million for the three months ended December 31, 2016, representing a decrease of 22.0% compared to the fourth quarter of 2015. Adjusted EBITDA was $73.9 million for the three months ended December 31, 2016, representing growth of 8.8% compared to the fourth quarter of 2015. Adjusted Net Income was $45.9 million for the three months ended December 31, 2016, representing 22.3% growth compared to the fourth quarter of 2015. Adjusted Net Income per diluted share was $0.71 for the three months ended December 31, 2016, representing 20.3% growth compared to the fourth quarter of 2015. A reconciliation of our non-GAAP measures, including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Net Income per share and our 2017 guidance, to the corresponding GAAP measures is included in this press release. For the twelve months ended December 31, 2016, service revenue was $1,580.0 million, which represents growth of 14.8%, or $204.2 million, compared to the twelve months ended December 31, 2015 at actual foreign exchange rates.  On a constant currency basis, service revenue grew $209.5 million, representing growth of 15.2% compared to the twelve months ended December 31, 2015. GAAP income from operations was $162.3 million, GAAP net income was $68.2 million and GAAP net income per diluted share was $1.06 for the twelve months ended December 31, 2016. Adjusted Net Income was $162.3 million for the twelve months ended December 31, 2016, an improvement of 28.6% compared to the same period in 2015.  Adjusted Net Income per diluted share was $2.52 for the twelve months ended December 31, 2016, up 26.0% compared to the same period in 2015. For Full Year 2017, the Company expects to achieve service revenues between $1.795 billion and $1.835 billion, representing constant currency growth of 14% to 16%, GAAP net income per diluted share between $2.46 and $2.56 per share, representing growth of 132% to 142%, Adjusted Net Income per diluted share between $3.08 and $3.18 per share, representing growth of 22% to 26%, and annual effective income tax rate estimates at approximately 27%. For Q1 2017, the Company expects to achieve service revenues between $415 million and $425 million, representing constant currency growth of 11% to 14%, GAAP net income per diluted share between $0.41 and $0.46 per share, Adjusted Net Income per diluted share between $0.57 and $0.62 per share, and annual effective income tax rate estimates at approximately 27%. All financial guidance assumes a EURO rate of 1.11 and a GBP rate of 1.35. All other foreign currency exchange rates are as of January 31, 2017. PRA will host a conference call at 9:00 a.m. ET on February 23, 2017, to discuss the contents of this release and other relevant topics. To participate, please dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes before the scheduled start of the call. The conference ID for the call is 66572766. The conference call will also be accessible, live via audio broadcast, on the Investor Relations section of the PRA website at www.prahs.com/investors. A replay of the conference call will be available online at www.prahs.com/investors. In addition, an audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 66572766. PRA (NASDAQ:PRAH) is one of the world’s leading global contract research organizations, or CROs, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and over 13,000 employees worldwide. Since 2000, PRA has performed approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. PRA has therapeutic expertise in areas that are among the largest in pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. PRA believes that it provides its clients with one of the most flexible clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. The Company has invested in medical informatics and clinical technologies designed to enhance efficiencies, improve study predictability and provide better transparency to clients throughout their clinical development processes. To learn more about PRA, please visit www.prahs.com. Internet Posting of Information: The Company routinely posts information that may be important to investors in the ‘Investor Relations’ section of the Company’s website at www.prahs.com. The Company encourages investors and potential investors to consult the Company’s website regularly for important information about the Company. This press release contains forward-looking statements that reflect, among other things, the Company’s current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, market trends or industry results to differ materially from those expressed or implied by such forward-looking statements. For this purpose, any statements contained herein that are not statements of historical fact may constitute forward-looking statements. Without limiting the foregoing, words such as “anticipates,” “believes,” “estimates,” “expects,” “guidance,” “intends,” “may,” “plans,” “projects,” “should,” “targets,” “will” and the negative thereof and similar words and expressions are intended to identify forward-looking statements. Actual results may differ materially from the Company’s expectations due to a number of factors, including that most of the Company’s contracts may be terminated on short notice and that the Company may be unable to maintain large customer contracts or to enter into new contracts; the historical indications of the relationship of backlog to revenues may not be indicative of their future relationship; the market for the Company’s services may not grow as the Company expects; the Company may under price contracts or overrun its cost estimates, and if the Company is unable to achieve operating efficiencies or grow revenues faster than expenses, operating margins will be adversely affected; the Company may be unable to maintain information systems or effectively update them; customer or therapeutic concentration could harm the Company’s business; the Company’s business is subject to risks associated with international operations, including economic, political and other risks; the Company is also subject to a number of additional risks associated with its business outside the United States, including foreign currency exchange fluctuations and restrictive regulations, as well as the risks and uncertainties associated with the United Kingdom’s expected withdrawal from the European Union; government regulators or customers may limit the scope of prescription or withdraw products from the market, and government regulators may impose new regulations affecting the Company’s business; the Company may be unable to successfully develop and market new services or enter new markets; the Company’s failure to perform services in accordance with contractual requirements, regulatory standards and ethical considerations may subject it to significant costs or liability, damage its reputation and cause it to lose existing business or not receive new business; the Company’s services are related to treatment of human patients, and it could face liability if a patient is harmed; the Company has substantial indebtedness and may incur additional indebtedness in the future, which could adversely affect the Company’s financial condition; and other factors that are set forth in the Company’s filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K filed with the SEC on February 25, 2016. The Company undertakes no obligation to update any forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Use of Non-GAAP Financial Measures This press release includes EBITDA, Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income per share, each of which are financial measures not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Management believes that these measures provide useful supplemental information to management and investors regarding our operating results as they exclude certain items whose fluctuation from period- to period do not necessarily correspond to changes in the operating results of our business. As a result, management and our board of directors regularly use EBITDA and Adjusted EBITDA as a tool in evaluating our operating and financial performance and in establishing discretionary annual bonuses. Adjusted EBITDA is also the basis for covenant compliance EBITDA, which is used in certain covenants in the credit agreement governing our senior secured credit facilities and the indenture governing the senior notes. In addition, management believes that EBITDA, Adjusted EBITDA and Adjusted Net Income (including diluted adjusted net income per share) facilitate comparisons of our operating results with those of other companies by backing out of GAAP net income items relating to variations in capital structures (affecting interest expense), taxation, and the age and book depreciation of facilities and equipment (affecting relative depreciation expense), which may vary for different companies for reasons unrelated to operating performance. We believe that EBITDA, Adjusted EBITDA and Adjusted Net Income (including diluted adjusted net income per share) are frequently used by securities analysts, investors, and other interested parties in the evaluation of issuers, many of which also present EBITDA, Adjusted EBITDA and Adjusted Net Income (including diluted adjusted net income per share) when reporting their results in an effort to facilitate an understanding of their operating results. These non-GAAP financial measures have limitations as analytical tools, and you should not consider these measures in isolation, or as a substitute for analysis of our results as reported under GAAP. Additionally, because not all companies use identical calculations, these presentations of EBITDA, Adjusted EBITDA and Adjusted Net Income (including diluted adjusted net income per share) may not be comparable to similarly titled measures of other companies. EBITDA represents net income before interest, taxes, depreciation and amortization. Adjusted EBITDA and Adjusted Net Income (including diluted adjusted net income per share) represent EBITDA and net income (including diluted net income per share), respectively, adjusted to exclude  stock-based compensation expense, loss (gain) on disposal of fixed assets, loss on modification or extinguishment of debt, foreign currency losses and gains, other (expense) income, equity in (gains) losses of unconsolidated joint ventures, transaction-related cost, acquisition-related costs, severance costs and restructuring charges, prior year foreign research and development credits, lease termination costs,  non-cash rent adjustments and other charges. Adjusted Net Income is also adjusted to exclude amortization of intangible assets, amortization of terminated interest rate swaps, and amortization of deferred financing costs. EBITDA, Adjusted EBITDA and Adjusted Net Income are not measurements of our financial performance under GAAP and should not be considered as alternatives to net income or other performance measures derived in accordance with GAAP or as alternatives to cash flow from operating activities as measures of our liquidity. EBITDA, Adjusted EBITDA and Adjusted Net Income have limitations as analytical tools, and you should not consider such measures either in isolation or as substitutes for analyzing our results as reported under GAAP. Some of these limitations are: Because of these limitations, EBITDA and Adjusted EBITDA should not be considered as discretionary cash available to us to reinvest in the growth of our business or as a measure of cash that will be available to us to meet our obligations. Constant currency comparisons are based on translating local currency amounts in the current year period at actual foreign exchange rates for the prior year. The Company routinely evaluates its financial performance on a constant currency basis in order to facilitate period- to- period comparisons without regard to the impact of changing foreign currency exchange rates. (a) Stock-based compensation expense represents the amount of recurring non-cash expense related to the Company’s equity compensation programs, excluding transaction-related stock-based compensation discussed in footnote (g). (b) Loss on disposal of fixed assets represents the costs incurred in connection with the sale or disposition of fixed assets, primarily IT equipment and furniture and fixtures. We exclude these losses from Adjusted EBITDA and Adjusted Net Income because they result from investing decisions rather than from decisions made related to our ongoing operations. (c) Loss on extinguishment of debt relates to costs incurred in connection with changes to our long-term debt. We exclude these losses from Adjusted EBITDA and Adjusted Net Income because they result from financing decisions rather than from decisions made related to our ongoing operations. (d) Foreign currency (gains) losses, net primarily relates to gains or losses that arise in connection with the revaluation of short-term inter-company balances between our domestic and international subsidiaries. In addition, this amount includes gains or losses from foreign currency transactions, such as those resulting from the settlement of third-party accounts receivable and payables denominated in a currency other than the local currency of the entity making the payment. We exclude these gains and losses from Adjusted EBITDA and Adjusted Net Income because they result from financing decisions rather than from decisions made related to our ongoing operations and because fluctuations from period- to- period do not necessarily correspond to changes in our operating results. (e) Other non-operating (income) expense, net represents income and expense that are non-operating and whose fluctuations from period- to -period do not necessarily correspond to changes in our operating results. (f) The foreign research and development credits are the result of a comprehensive analysis we have been performing across the organization to determine whether expenditures incurred qualify as research and development as defined by the respective jurisdiction.  The amounts recorded in this line item represent amounts recorded in the current period that related to a prior period. (g) Transaction-related costs primarily relate to costs incurred in connection with the March, May and November 2016 secondary offerings and receivables financing agreement. These costs include $32.0 million of non-cash stock-based compensation expense related to the vesting and release of the transfer restrictions of certain performance-based stock options and $10.1 million of stock-based compensation expense associated with the release of the transfer restrictions on a portion of service-based vested options in connection with the announcement of our March, May and November 2016 secondary offerings. In addition, we incurred $2.7 million of third-party fees associated with the secondary offerings and the closing of our accounts receivable financing agreement. (h) Acquisition-related costs primarily relate to costs incurred in connection with purchase of the assets of Value Health Solutions, Inc., the acquisition of Nextrials, Inc., and the integration cost for the Takeda joint venture, as well as costs related to other potential acquisitions to enhance our strategic objectives. (i) Lease termination expenses represent charges incurred in connection with the termination of leases at locations that are no longer being used by the Company. (j) Severance and restructuring charges represent amounts incurred in connection with the elimination of redundant positions within the organization, including positions eliminated in connection with the KKR Transaction and the acquisitions of ClinStar, RPS and CRI Lifetree. (k) We have escalating leases that require the amortization of rent expense on a straight-line basis over the life of the lease. The non-cash rent adjustment represents the difference between rent expense recorded in the consolidated statement of operations and the amount of cash actually paid. (l) Represents charges incurred that are not considered part of our core operating results. (m) Represents the tax effect of the total adjustments at our estimated effective tax rate.


News Article | February 15, 2017
Site: www.marketwired.com

MONTRÉAL, QUÉBEC--(Marketwired - 8 fév. 2017) - Theratechnologies inc. (« Theratechnologies ») (TSX:TH) a annoncé aujourd'hui ses résultats financiers pour l'exercice clos le 30 novembre 2016. « Notre dernier exercice s'est révélé à la fois valorisant et stimulant. Nous avons terminé l'exercice avec nos meilleurs résultats à ce jour en regard des ventes de notre produit. En fait, EGRIFTAMD est devenu l'assise sur laquelle nous pouvons nous appuyer pour aller plus loin. En outre, EGRIFTAMD a rendu possible l'acquisition des droits de commercialisation de l'ibalizumab, lequel présente un potentiel considérable et qui pourrait, s'il est approuvé par la FDA, rapporter des revenus supplémentaires importants à la Société », a déclaré M. Luc Tanguay, président et chef de la direction de Theratechnologies inc. « La transaction portant sur l'ibalizumab pourrait s'avérer un point décisif pour l'avenir de notre Société », a conclu M. Tanguay. Nous prévoyons que, prises isolément, les activités se rapportant à EGRIFTAMD pour la période de 12 mois qui se terminera le 30 novembre 2017 devraient générer des ventes nettes se chiffrant entre 40 000 000 $ et 42 000 000 $. Cet estimé a été établi sur la base d'un taux de change entre le dollar américain et le dollar canadien de 1,32. Nous mettons actuellement la touche finale aux plans entourant le lancement de l'ibalizumab aux États-Unis, qui, nous le croyons, devrait avoir lieu en 2017, s'il est approuvé. Le 1er mars 2017, nous rendrons public nos plans ainsi que de nouvelles prévisions concernant l'incidence de ces plans sur nos ventes et notre BAIIA ajusté. Les résultats financiers présentés dans le présent communiqué de presse sont tirés du rapport de gestion et des états financiers consolidés audités de la Société pour la période de 12 mois close le 30 novembre 2016, lesquels ont été établis conformément aux Normes internationales d'information financière (les International Financial Reporting Standards, ou « IFRS »), publiées par l'International Accounting Standards Board (l'« IASB »). Le rapport de gestion et les états financiers consolidés audités sont disponibles au www.sedar.com et au www.theratech.com. Sauf indication contraire, tous les montants figurant dans le présent communiqué de presse sont présentés en dollars canadiens et les termes clés ont le sens qui leur est attribué dans notre rapport de gestion. Aux fins de la présente, EGRIFTAMD fait référence à la tésamoréline, utilisée pour la réduction de l'excès de graisse abdominale chez les patients infectés par le VIH et atteints de lipodystrophie. EGRIFTAMD est notre marque de commerce. Les revenus consolidés ont atteint 37 072 000 $ pour la période de 12 mois close le 30 novembre 2016, en regard de 30 055 000 $ pour l'exercice 2015. Les revenus tirés des ventes nettes ont augmenté de 24 % en 2016 grâce à des ventes unitaires plus élevées, à des variations des cours de change favorables et à des prix supérieurs. Un paiement initial de 200 000 $ avait été reçu en 2015 dans le cadre du partenariat commercial avec AOP. Le coût des ventes s'est établi à 6 658 000 $ pour la période de 12 mois close le 30 novembre 2016, par rapport à 4 024 000 $ pour l'exercice 2015. Pour l'exercice 2016, le coût des ventes tient compte des redevances de 2 430 000 $ qui doivent être payées sur les ventes depuis le 1er janvier 2016 aux termes de la convention de résiliation de licence d'EMD Serono. Pour l'exercice 2016, un recouvrement de coûts de production non attribués de 86 000 $ a été comptabilisé alors que pour l'exercice 2015, le coût des ventes tenait compte de coûts de production non attribués de 338 000 $, dont une tranche de 229 000 $ était liée à la dépréciation des stocks. Les frais de R&D, déduction faite des crédits d'impôt, se sont chiffrés à 6 955 000 $ pour la période de 12 mois close le 30 novembre 2016, comparativement à 4 905 000 $ pour l'exercice 2015. La majeure partie de la hausse par rapport à l'exercice précédent est attribuable à l'augmentation des dépenses liées aux affaires médicales dans la poursuite de notre objectif visant à élargir le bassin de patients utilisant EGRIFTAMD. Les affaires médicales englobent essentiellement les programmes d'éducation médicale faisant appel à des médecins et à des infirmières qui sont des leaders d'opinion travaillant auprès des porteurs du VIH afin de les familiariser avec les données scientifiques en lien avec EGRIFTAMD et à ses avantages thérapeutiques. Les frais de R&D comprennent également les coûts liés à nos deux essais de phase IV, coûts qui se sont élevés à 2 341 000 $ au cours de la période de 12 mois close le 30 novembre 2016, comparativement à 2 771 000 $ pour l'exercice 2015. Les affaires réglementaires, l'assurance de la qualité et le projet de formulation F4 sont d'autres composantes des frais de R&D. Les frais de vente et de développement des marchés ont atteint 14 658 000 $ pour la période de 12 mois close le 30 novembre 2016, contre 12 926 000 $ pour l'exercice 2015. Désormais, les frais de vente et de développement des marchés comprennent les coûts liés au maintien de notre propre équipe de vente, ainsi qu'aux différents éléments de notre programme de mise en marché, dont notre groupe de marketing, notre centre d'appels, nos services de remboursement et les campagnes promotionnelles ayant pour but d'accroître la notoriété d'EGRIFTAMD et de ses avantages thérapeutiques au sein de la communauté VIH. Au cours de l'exercice 2016, nous avons également commencé à engager des coûts liés au lancement prévu de l'ibalizumab en 2017. Les frais de vente et de développement des marchés comprennent l'amortissement de la valeur des immobilisations incorporelles établi pour les droits de commercialisation d'EGRIFTAMD. Cette charge d'amortissement s'est chiffrée à 2 007 000 $ pour l'exercice 2016, comparativement à 1 905 000 $ pour l'exercice 2015. Les frais généraux et administratifs ont totalisé 4 863 000 $ pour la période de 12 mois close le 30 novembre 2016, comparativement à 4 055 000 $ pour l'exercice 2015. La hausse des frais pour l'exercice 2016 est principalement attribuable à la rémunération fondée sur des actions (une charge hors trésorerie) et à l'embauche d'un chef de la direction financière. Le BAIIA ajusté pour la période de 12 mois close le 30 novembre 2016 a atteint 6 573 000 $, comparativement à 6 439 000 $ pour l'exercice 2015. Cette légère amélioration du BAIIA ajusté pour l'exercice 2016 a été comptabilisée malgré l'incidence sur le bénéfice de la charge au titre des redevances d'EGRIFTAMD de 2 430 000 $ et des coûts de plus de 1 000 000 $ liés au lancement prévu de l'ibalizumab, lesquels n'avaient pas été engagés pour l'exercice 2015. Se reporter à la rubrique « Mesures financières non conformes aux IFRS » ci-après. Compte tenu des variations des revenus et des charges dont il est question ci-dessus, nous avons inscrit un bénéfice net de 410 000 $, ou 0,01 $ par action (0,01 $ par action après dilution), pour la période de 12 mois close le 30 novembre 2016, en comparaison d'un bénéfice net de 1 571 000 $, ou 0,03 $ par action (0,02 $ par action après dilution), pour l'exercice 2015. Pour la période de 12 mois close le 30 novembre 2016, les activités d'exploitation ont généré des flux de trésorerie de 2 691 000 $, contre des flux de trésorerie de 7 086 000 $ pour l'exercice 2015. La réduction des flux de trésorerie s'explique en grande partie par la variation des actifs et des passifs d'exploitation. Les principales composantes de cette variation sont le recul de 2 158 000 $ des créditeurs et charges à payer et la hausse de 2 101 000 $ des clients et autres débiteurs. Au cours de l'exercice 2016, la Société a versé à EMD Serono des paiements de 5 196 000 $ à titre de règlement partiel de son obligation à long terme (5 398 000 $ pour l'exercice 2015). Le 6 août 2015, la Société a conclu un appel public à l'épargne visant 4 600 000 unités qui a donné lieu à un produit brut de 11 040 000 $. Chaque unité était constituée d'une action ordinaire et d'un demi-bon de souscription d'actions ordinaires de la Société, chaque bon de souscription entier (un « bon de souscription ») pouvant être exercé pendant une période de 24 mois à compter de la date de clôture du placement à un prix d'exercice de 3,00 $ l'action. Aux termes des IFRS, le traitement prescrit pour les bons de souscription émis à un prix d'exercice libellé en monnaie étrangère, le dollar canadien dans ce cas-ci, prévoit que ces bons de souscription soient classés à titre de passif évalué à la juste valeur. Les frais d'émission d'actions payés en 2015 avaient totalisé 1 126 000 $, ce qui a donné lieu à un produit net de 9 914 000 $. Les revenus consolidés se sont chiffrés à 10 377 000 $ pour le trimestre clos le 30 novembre 2016, en regard de 9 011 000 $ pour la période correspondante de 2015. Les revenus tirés des ventes nettes ont atteint 10 376 000 $ pour le trimestre clos le 30 novembre 2016, contre 9 007 000 $ pour la période correspondante de l'exercice 2015. Cette hausse de 15 % est attribuable aux hausses des ventes unitaires et des prix. Le coût des ventes s'est établi à 1 978 000 $ pour le trimestre clos le 30 novembre 2016, par rapport à 1 161 000 $ pour la période correspondante de l'exercice 2015. Le coût des ventes pour le quatrième trimestre de 2016 comprend une charge au titre des redevances de 757 000 $, lesquelles doivent être payées sur les ventes depuis le 1er janvier 2016 aux termes de la convention de résiliation de licence d'EMD Serono. Les frais de R&D, déduction faite des crédits d'impôt, se sont chiffrés à 1 158 000 $ pour le trimestre clos le 30 novembre 2016, comparativement à 926 000 $ pour la même période un an plus tôt. Les coûts liés aux deux essais cliniques de phase IV (soit l'étude d'observation et l'étude sur la rétinopathie) se sont établis à 310 000 $ pour le trimestre clos le 30 novembre 2016, par rapport à 265 000 $ pour le trimestre correspondant de l'exercice 2015. L'intensification des activités liées aux affaires médicales, aux affaires réglementaires et à l'assurance de la qualité, compte pour la quasi-totalité de l'écart résiduel entre le montant des frais de R&D du quatrième trimestre de l'exercice 2016 et celui du quatrième trimestre de l'exercice précédent. Les frais de vente et de développement des marchés ont atteint 3 762 000 $ pour le trimestre clos le 30 novembre 2016, en regard de 4 348 000 $ pour la période correspondante de l'exercice 2015. Le niveau plus élevé des frais en 2015 s'explique essentiellement par l'augmentation prévue des activités de vente et de développement des marchés qui s'est enclenchée au quatrième trimestre de 2015 et qui s'est poursuivie au début de l'exercice 2016. Les frais de vente et de développement des marchés comprennent également l'amortissement de la valeur des immobilisations incorporelles établie pour les droits de commercialisation d'EGRIFTAMD. Cette charge d'amortissement s'est chiffrée à 501 000 $ pour le trimestre clos le 30 novembre 2016, comparativement à 499 000 $ pour la même période un an plus tôt. Les frais généraux et administratifs ont totalisé 1 385 000 $ pour le trimestre clos le 30 novembre 2016, alors qu'ils avaient totalisé 1 157 000 $ pour le trimestre correspondant de l'exercice 2015. Les activités d'exploitation se sont soldées par un bénéfice de 1 455 000 $ pour le trimestre clos le 30 novembre 2016, contre 1 419 000 $ pour le trimestre correspondant de l'exercice 2015. Le BAIIA ajusté pour le trimestre clos le 30 novembre 2016 a atteint 2 812 000 $, comparativement à 2 185 000 $ pour la période correspondante de l'exercice 2015. Une augmentation du BAIIA ajusté au quatrième trimestre de l'exercice 2016 a été comptabilisée malgré l'incidence sur le bénéfice de la charge au titre des redevances d'EGRIFTAMD et des coûts liés au lancement prévu de l'ibalizumab, lesquels n'avaient pas été engagés pour l'exercice 2015. Se reporter à la rubrique « Mesures financières non conformes aux IFRS » ci-après. Compte tenu des variations des revenus et des charges mentionnées ci-dessus, nous avons inscrit un bénéfice net de 173 000 $, ou 0,00 $ par action, pour le trimestre clos le 30 novembre 2016, en comparaison d'un bénéfice net de 488 000 $, ou 0,01 $ par action, pour le trimestre correspondant de l'exercice 2015. Pour le trimestre clos le 30 novembre 2016, les activités d'exploitation ont généré des flux de trésorerie de 2 688 000 $, contre des flux de trésorerie de 3 233 000 $ pour la période correspondante de l'exercice 2015. L'accroissement des charges hors trésorerie en 2016 s'explique en grande partie par la hausse des charges financières susmentionnée. L'apport des variations des actifs et des passifs d'exploitation aux flux de trésorerie s'est établi à 446 000 $ pour l'exercice 2016, comparativement à 1 647 000 $ pour l'exercice précédent, ce qui rend compte des importantes variations de l'apport des postes suivants : Clients et autres débiteurs, Stocks, Créditeurs et charges à payer et Provisions. Toutes ces variations ont eu lieu dans le cours normal des activités. Le 5 décembre 2016, la Société a réalisé un appel public à l'épargne visant la vente et l'émission de 5 323 000 actions ordinaires pour une contrepartie en trésorerie brute de 16 501 000 $. Les frais d'émission d'actions sont estimés à 1 490 000 $, ce qui a donné lieu à un produit net de 15 011 000 $. La Société a attribué aux preneurs fermes une option de surallocation pour la vente et l'émission de 798 450 actions ordinaires supplémentaires à un prix d'émission de 3,10 $ par action, exerçable pendant une période de 30 jours à compter de la date de clôture. L'option de surallocation n'a pas été exercée. La Société a également émis des options de courtier pour la vente et l'émission de 212 920 actions ordinaires à un prix d'émission de 3,10 $ par action, exerçables pendant une période de 18 mois à compter de la date de clôture. En janvier 2017, les 124 000 bons de souscription de courtier restants, émis au cours de l'exercice 2015, ont été exercés. De plus, 124 000 actions ordinaires et 62 000 bons de souscription d'actions ordinaires ont été émis pour une contrepartie en trésorerie de 297 600 $. Le BAIIA ajusté est une mesure non conforme aux IFRS. Un rapprochement du BAIIA ajusté est présenté dans le tableau qui suit. Nous utilisons des mesures financières ajustées pour évaluer notre performance d'exploitation. La réglementation en valeurs mobilières exige que les sociétés informent les lecteurs que le résultat et toute autre mesure ajustée selon des paramètres autres que les IFRS n'ont aucun sens normalisé et qu'il est donc peu probable qu'ils soient comparables aux mesures semblables utilisées par d'autres sociétés. Par conséquent, ces mesures ne doivent pas être considérées de façon isolée. Nous utilisons le BAIIA ajusté pour mesurer notre performance d'exploitation d'une période à l'autre sans tenir compte des variations provoquées par divers ajustements pouvant fausser l'analyse des tendances à l'égard de nos activités et parce que nous croyons que cette mesure procure des renseignements utiles sur notre situation financière et nos résultats d'exploitation. Nous parvenons au BAIIA ajusté en ajoutant au bénéfice net ou à la perte nette les produits financiers et les charges financières, les amortissements, l'impôt ainsi que les crédits d'impôt à l'investissement fédéraux de l'ARC inscrits en 2014. Nous excluons aussi l'incidence de certaines transactions non monétaires, telles que la rémunération fondée sur des actions pour le régime d'options d'achat d'actions ainsi que la dépréciation des stocks, dans le calcul du BAIIA ajusté. Nous estimons qu'il est utile d'exclure ces éléments puisqu'ils représentent des charges hors trésorerie, qu'ils échappent au contrôle de la direction à court terme, ou qu'ils n'ont pas d'incidence sur la performance d'exploitation principale. L'exclusion de ces éléments ne signifie pas qu'ils sont nécessairement non récurrents. Les charges de rémunération fondées sur des actions sont une composante de la rémunération des employés et elles peuvent varier considérablement selon le cours des actions de la Société. De plus, d'autres éléments sans incidence sur la performance d'exploitation principale de la Société peuvent varier considérablement d'une période à l'autre. Ainsi, le BAIIA ajusté permet de mieux suivre l'évolution des résultats d'exploitation au fil du temps aux fins de leur comparaison. Il se pourrait que notre méthode de calcul du BAIIA ajusté soit différente de celle utilisée par d'autres sociétés. Une conférence téléphonique aura lieu aujourd'hui à compter de 8 h 30 (HE) pour discuter des résultats. Les analystes financiers seront invités à poser des questions lors de la conférence téléphonique. Les membres des médias et autres personnes intéressées sont invités à la conférence à titre d'auditeurs uniquement. Pour accéder à la conférence téléphonique, veuillez composer le 1-877-223-4471 (Amérique du Nord) ou le 1-647-788-4922 (international). L'appel sera également accessible par webdiffusion au http://www.gowebcasting.com/8293. L'enregistrement audio de cette conférence sera disponible deux heures après la fin de l'appel, et ce, jusqu'au 22 février 2017, au 1-800-585-8367 (Amérique du Nord) ou au 1-416-621-4642 (international) en saisissant le code d'accès 49662824. Theratechnologies (TSX:TH) est une société pharmaceutique spécialisée répondant à des besoins médicaux non satisfaits en vue de promouvoir auprès des patients infectés par le VIH un mode de vie sain et une qualité de vie améliorée. D'autres renseignements sur Theratechnologies sont disponibles sur le site Web de la Société au www.theratech.com et sur SEDAR au www.sedar.com. Le présent communiqué de presse renferme des énoncés prospectifs et de l'information prospective (collectivement, les « énoncés prospectifs ») au sens de la législation applicable en valeurs mobilières. Ces énoncés prospectifs reposent sur les opinions et les hypothèses de la direction ou sur l'information disponible à la date où ils sont formulés et se reconnaissent à l'emploi de mots tels que « peut », « va », « pourrait », « voudrait », « devrait », « perspectives », « croit », « planifie », « envisage », « prévoit », « s'attend » et « estime » ou la forme négative de ces termes ou des variations de ceux-ci. Les énoncés prospectifs contenus dans le présent communiqué de presse comprennent, sans toutefois s'y limiter, des énoncés portant sur les revenus et le BAIIA ajusté que nous prévoyons enregistrer pour l'exercice 2017, sur les revenus que nous anticipons générer des ventes de l'EGRIFTAMD pour l'exercice 2017, l'approbation d'ibalizumab et la croissance de nos revenus une fois ibalizumab approuvé et commercialisé. Les énoncés prospectifs sont fondés sur un certain nombre d'hypothèses, notamment celles voulant que les ventes d'EGRIFTAMD continueront de croître et que nous rencontrerons nos prévisions de vente anticipées concernant EGRIFTAMD pour l'exercice 2017, le taux de change USD/CAD ne fluctuera pas au cours de l'exercice 2017, la FDA n'émettra pas d'ordonnance ou de décision ayant l'effet d'affecter de façon défavorable la commercialisation d'EGRIFTAMD aux États-Unis, ibalizumab sera approuvé par la FDA aux États-Unis et nous débuterons la commercialisation d'ibalizumab d'ici la fin de 2017, de même que l'ibalizumab sera accepté comme médicament, si approuvé, par les médecins et les patients. Les énoncés prospectifs sont assujettis à plusieurs risques et incertitudes, dont bon nombre sont indépendants de notre volonté et sont susceptibles d'entraîner un écart considérable entre les résultats réels et ceux qui sont exprimés, expressément ou implicitement, dans les énoncés prospectifs figurant dans le présent communiqué de presse. Ces risques visent notamment une baisse des ventes de l'EGRIFTAMD au cours de l'exercice 2017, un rappel visant EGRIFTAMD, l'émission d'une ordonnance ou décision par la FDA affectant de façon défavorable la commercialisation d'EGRIFTAMD, le non-dépôt auprès de la FDA d'une demande d'approbation pour l'ibalizumab, la non-approbation de l'ibalizumab par la FDA et, même si approuvé, le fait que nous ne soyons pas en mesure de lancer et de commercialiser l'ibalizumab d'ici la fin de 2017. Les investisseurs éventuels sont priés de se reporter à la rubrique « Risques et incertitudes » de notre notice annuelle en date du 7 février 2017 pour tout autre risque additionnel concernant nos activités. Le lecteur est prié d'examiner ces risques et incertitudes attentivement et de ne pas se fier indûment aux énoncés prospectifs. Les énoncés prospectifs reflètent les attentes actuelles concernant des événements futurs. Ils ne sont valables qu'à la date de ce communiqué de presse et traduisent nos attentes à cette date. Nous ne nous engageons aucunement à mettre à jour ou à réviser l'information contenue dans ce communiqué de presse, que ce soit à la suite de l'obtention de nouveaux renseignements, à la suite de nouveaux événements ou circonstances ou pour toute autre raison que ce soit, sauf si les lois en vigueur l'exigent.


News Article | March 2, 2017
Site: www.prnewswire.co.uk

NEW YORK, March 2, 2017 /PRNewswire/ -- J.F. Lehman & Company, a leading middle-market private equity firm focused on the aerospace, maritime and defense industries, has completed fundraising for JFL Equity Investors IV, L.P. and affiliated investment vehicles ("JFL IV").  The partnerships were oversubscribed and closed on commitments of $833 million, reaching JFL IV's hard cap and exceeding its target of $700 million due to strong support from existing investors and demand from new clients. Capital commitments were secured from a diversified group of more than four dozen institutions based in North America and Europe. Investors include leading public and private pension funds, insurance companies, fund-of-funds, family offices, endowments and foundations. Additional commitments were provided by members of J.F. Lehman & Company's Operating Executive Board, individual investors and the firm's general partners. "The successful marketing of JFL IV represents a key milestone for our organization, and we are grateful for the strong support and confidence received from the institutional investor community," said Louis N. Mintz, Partner. "The demand for JFL IV clearly reflects the success of our dedicated, sector-focused strategy and strength of our team." For the entirety of its 25-year history, J.F. Lehman & Company has focused exclusively on the aerospace, maritime and defense industries and the technologies that originate from them. Consistent with the firm's historical investment program, JFL IV will focus on control ownership positions in leveraged acquisitions of high quality companies in the firm's target industries that are headquartered in the United States and United Kingdom. The firm's previous private equity vehicles include the 2011-vintage JFL Fund III with commitments of $575 million, JFL Fund II ($335 million) and JFL Fund I ($130 million). Stanwich Advisors, LLC acted as the exclusive financial advisor and placement agent for the offering and Debevoise & Plimpton LLP provided legal counsel for the formation of the funds. Founded in 1992, J.F. Lehman & Company is a leading middle-market private equity firm focused exclusively on the defense, aerospace and maritime sectors.  The firm has offices in New York and Washington, D.C. For more information about J.F. Lehman & Company, please visit www.jflpartners.com.


Journal of DST is a Peer-Reviewed Bi-monthly Scientific Journal Indexed in the National Library of Medicine's Database, PubMed. They Publish the Largest Number of Articles on Diabetes Technology of any Journal in the World LOS ANGELES, CA--(Marketwired - February 08, 2017) - ViaDerma, Inc. ( : VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has been invited to write an article in a leading Diabetic publication, the "Journal of Diabetes Science and Technology." Dr. Otiko has also been selected to present his abstract at DFCON or the Diabetic Foot Global Conference in Houston, TX, March 23rd through the 25th. DFCon, website www.dfcon.com, is the premier international, interdisciplinary diabetic foot conference in North America. In its 15th year, the course is designed for the wide spectrum of generalists and specialists who diagnose and manage the diabetic foot. Didactic talks, panel discussions, Q&A sessions, specialty symposia and workshops will delve into diagnostic and interventional strategies for diabetic foot ulcers and amputation prevention. Featuring a world-renowned international faculty, DFCon offers the opportunity to review state-of-the-art concepts and techniques. "Diabetes affects almost a half a billion people globally with 23 million affected in the US. With about 83 million affected with condition designated as pre-diabetes. Of those with diabetes, 50% will develop peripheral neuropathy and/or diabetic ulcers. Of the 23 million people affected with diabetes, 25% will develop diabetic ulcers many will require expensive therapy or invasive surgical amputations. The goal of this study was to evaluate the efficacy and safety of the FDA registered OTC medication Viabecline. A topically applied antibiotic ointment designed to treat infections in cuts, scrapes and burns, we found that Viabecline is very effective as part of a diabetic foot ulcer (DFU) treatment protocol. Clinical investigation (CI) documenting the treatment effectiveness was estimated by enrolling patients in a multi-center outpatient clinic setting," said CEO Dr. Christopher Otiko. "The results conclude Viabecline is more effective than standard care in treating DFU's, including IV antibiotics. The effect was greatest in those with the most severe wounds, i.e., large wounds that affect deeper anatomical structures. These patients were last resort patients that had failed all previous care and were headed to an amputation. In some cases, even an amputation wasn't feasible because of the patient's cardiac status. Viabecline is more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said CEO Dr. Christopher Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols." "We are also in the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko. ViaDerma, Inc. ( : VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD's and THC with the delivery system was filed in 2014. The use of CBD's is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.


News Article | February 15, 2017
Site: www.prweb.com

HIPOWER SYSTEMS, a manufacturer of power-generation and power distribution equipment in the U.S. and Canada, today announced that the enclosures used in its prime power and standby generators have been certified by a classifying engineering firm to withstand winds of up to 180 miles per hour (MPH). “With this certification, companies in areas where extreme winds occur can have even greater confidence in the strength and stability of our generator enclosures,” said HIPOWER SYSTEMS President Rafael Acosta. “Although high winds are normally associated with major storms, such as tornadoes or hurricanes, they can occur almost anywhere and at any time—from the windswept plains of North America to the top of a Manhattan skyscraper. Our enclosures are built to withstand all but the most extreme—and infrequent—winds.” When evaluating the HIPOWER SYSTEMS enclosures, engineers considered a wide array of criteria, ranging from enclosure materials, roof live-load limitations and maximum wind pressure on walls to such minutiae as mounting hardware tensile strength and stress resistance. Resistance to overturn forces, with wind coming from various directions, was also an important part of the calculation. For the evaluations, the engineering firm used three key building specifications: Of particular interest for wind-prone communities is adherence to the FBC, a set of building standards, designed by the state of Florida, that are considered important benchmarks for wind protection. The 180 MPH rating also meets the extremely stringent standards for Florida’s Broward County Risk Category IV for buildings and structures. This category, which is composed of buildings and structures housing “essential facilities”—emergency preparedness facilities, national defense stations, emergency backup stations and other crisis-response locations—must adhere to the highest feasible level of wind resistance. “This certification confirms that HIPOWER SYSTEMS enclosures would have withstood the sustained wind speeds of even the strongest hurricane on record—Hurricane Wilma, which attained speeds of 175 MPH,” said Acosta. “It well exceeds the highest non-tornadic wind gust ever recorded in famously ‘windy’ North Dakota, which was 143 MPH.” About HIPOWER SYSTEMS HIPOWER SYSTEMS (a division of Himoinsa, S.L.; a member of the YANMAR Co. Ltd group of companies) is the principal supplier of power distribution and prime, standalone power-generation equipment and packages to the U.S. and Canadian markets, serving the Residential, Commercial and Industrial sectors including the Agriculture, Telecommunications, Health Care and Oil & Gas Industries. The company builds and customizes backup generators, diesel generators, natural gas generators and alternative bi-fuel generator sets from 8kW to 3MW with a complete range of accessories, including automatic transfer switches, paralleling switchgear, UL tanks, enclosures and power distribution equipment. In North America and throughout the globe, our rental packages and power distribution equipment are recognized as the best power solution source for emergency and disaster relief. For more information, visit http://www.hipowersystems.com.


News Article | February 28, 2017
Site: www.prweb.com

A February 15th article in The Sun describes an experimental resin-based technique that could eventually treat some cavities without the need for drilling or any type of anesthesia. Los Angeles area clinic Smile Boutique Beverly Hills says that, while this is a very interesting avenue for repairing cavities that may eventually benefit a great many dental patients, there are already plenty of highly innovative leading edge treatments that have made modern day dentistry more effective and comfortable than ever for today’s patients. These include: Digital X-Rays and 3D Imaging: Smile Boutique Beverly Hills notes that it’s never been speedier or less difficult to obtain the information needed to fully and completely diagnose the state of a patient’s overall oral health. It notes that digital technology has made dental x-rays speedier and more convenient than ever before. The clinic adds that, for cosmetic dentistry patients, modern day cosmetic imaging allows patients to obtain a clear illustration of how a treatment will look once the entire process is complete, allowing them to make a fully informed choice about whether or not a procedure is right for them. Sedation Dentistry: Smile Boutique Beverly Hills notes that they pride themselves on their gentle and compassionate team of dental professionals and their ability to make patients as comfortable as possible at all times. Even so, for patients who are afflicted with dental phobias or otherwise nervous about a procedure, as well as for oral surgeries, the clinic notes that it offers a number of conscious sedation options. The clinic adds that its dental team works closely with patients to explore whether choices ranging from oral and IV sedation to general anesthesia and nitrous oxide are most appropriate in a given case. All-on-Four Dental Implants: Dental implants are by far the best way to deal with missing teeth, but replacing an entire row of teeth can be inconvenient and time consuming, notes Smile Boutique Beverly Hills. The clinics says, however, that all-on-four implants allow for an entire row of new teeth to be implanted in a single procedure so that patients can leave the dentist’s office with an attractive new smile. Smile Boutique Beverly Hills adds that it is delighted to offer the full range of the very latest and best in dental procedures, including laser teeth whitening, Waterlase dentistry, Invisalign invisible orthodontia and much more. Interested readers who would like to learn more about the finest dental boutique in the West Los Angeles/Beverly Hills area are invited to call (424) 281-0959 or they may visit its website at http://smileboutiquebeverlyhills.com/.


SAN CLEMENTE, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, today announced the time of its fourth quarter and fiscal year 2016 earnings release and conference call. The Company will release its fourth quarter and fiscal year 2016 results on Wednesday, March 1st, 2017 at approximately 4:00 p.m. EST (1:00 p.m. PST) and will be conducting a conference call concerning those results at 4:30 p.m. EST (1:30 p.m. PST) on Wednesday, March 1st, 2017. The call can be accessed at (800) 936-9761, international (408) 774-4587, and conference ID 72955804. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com, clicking on the Investors tab, clicking on the Webcast icon and following the prompts. The webcast will also be available by replay. ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells innovative medical devices used in vascular therapy, oncology and critical care applications. ICU Medical's product portfolio includes IV smart pumps, sets, connectors and solutions along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. In addition, the company manufactures automated pharmacy compounding systems with workflow technology, closed systems transfer devices for hazardous drugs, disposable blood pressure transducers, advanced sensor catheters, and cardiac monitoring systems. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical, Inc. can be found at www.icumed.com.


Arco Vara AS ning tema kontserni kuuluvate ettevõtete (edaspidi „kontsern“) tegevus hõlmab kinnisvaraarendust ning kinnisvaraga seotud teenuseid. Kontserni aktiivseteks turgudeks on Eesti, Läti ja Bulgaaria. Kontserni tegevus on jaotatud kaheks tegevussegmendiks: teenindusdivisjon ja arendusdivisjon. ·                     Kontserni laenukoormus on 31.12.2016 seisuga kasvanud 1,5 miljonit eurot võrreldes 2015. aasta lõpuga. Netolaenud on 2016. aasta 12 kuuga suurenenud 1,4 miljoni euro võrra, tasemele 13,4 miljonit eurot 31.12.2016 seisuga. Kontserni intressikandvate kohustuste kaalutud keskmine intressimäär oli 31.12.2016 seisuga 5,3%, mis on 0,3 protsendipunkti võrra kõrgem võrreldes 31.12.2015 seisuga. Arco Vara saab kohe 25-aastaseks. Mõni aasta tagasi me reanimeerisime ennast olukorrast, kuhu olime end ise viinud, kasvatades kiiremini varade ja kohustuste mahtu kui suutlikkust klientidele valmis kinnisvaratooteid müüa. Täna kogume uuesti kiirust, mis on valulikult aeglane protsess. Ma ei ole Arco Vara neljanda kvartali ja kogu 2016. aasta tulemuste üle uhke, kuid ei pea neid ka halvaks, sest ma näen, kuidas need viivad 2017. ja järgmistel aastatel müügini.  Arendustoodete eelmüük on meil olnud hea ning 2017. aastal kajastub see käibena. Hetkel peame rääkima siiski 2016. aasta numbritest. Alustan halvemast, kahjumist. Meie neljas kvartal, kus me ei müünud peaaegu tühjast laost ka midagi välja, muutis kogu aasta tulemust kehvemaks. Me ei saavutanud oma seatud aasta eesmärki: müüa kaupu ja teenuseid 10,3 miljoni euro eest ja teenida puhaskasumit vähemalt 0,8 miljonit eurot. Tegelik 2016. aasta tulemus (auditeerimata) on müügitulu 9,7 miljonit eurot ja kahjum 0,8 miljonit eurot, millest viimasesse andis neljas kvartal suurima panuse. Teiseks, kuna me ei olnud Madrid Blvd väljarentimisel edukad ning tänaseks sõlmitud lepingute rendihinnad on oodatust samuti madalamad, siis tuli juhatusel neljandas kvartalis ümber hinnata ka hoone õiglane väärtus. Hindasime hoone õiglast väärtust aasta lõpu seisuga alla 0,4 miljoni euro võrra. See osa kahjumist tekkis paberil, mitte rahas. Kolmandaks, me müüsime aastavahetusel ühekordse tehinguga Lätis asuvad välja arendamata eramukrundid „Baltezers-3“, millest IV kvartalisse tekkis kahjum 0,2 miljonit eurot. Selle tehinguga valisime kohe pakutud raha tulevikus võib-olla teenitava tulu ees. Arvestasime seejuures, et ajal, mil Arco Vara kontsern laenab arendustegevuseks võlakirjadena raha hinnaga üle 10% aastas, ei ole õige istuda aastaid arendamata maa otsas, mille jooksev tootlus on null ning rahavoog maamaksu jm kuludena negatiivne. Kogu Baltezers eramukruntide projekti (nii välja arendatud lõpptooted kui ka välja arendamata maa väärtuse) hindas juhatus alla 2012. aasta lõpu seisuga. Tuleb tunnistada, et toonane allahindlus ei olnud piisav. Välja arendatud lõpptooteid oleme sellest ajast müünud väikese kasumiga, kuid väga aeglaselt, ca 4-8 tükki aastas. Neljandaks, me kaotasime ca 0,2 miljonit eurot vahendus- ja hindamisteenuste osutamisega. Selles osas tuleb ainult peeglisse vaadata. Tänaseks on Läti teenindusüksus kontsernist välja müüdud. Võimalik on kaubamärgi ja tarkvara litsentseerimine. Bulgaaria ja eriti Eesti üksuses on läbi viidud olulised muudatused personalis, teenuse standardis, andmete töötlemisel, tulude jagamisel ning turunduses. Muudatustega ootame Bulgaarias ja Eestis jooksvasse kasumisse jõudmist 2017. aastal. Kui kokkuvõttes 2016. aasta kahjumi põhjuseid üldistada ja küsida tagantjärele tarkusena, mida oleks võinud teha teisiti, siis olulised vead tegime Madrid Blvd kontoripindadega. Madrid Blvd ebaõnnestumise kogumõju kasumiaruandele on üle 0,8 miljoni euro. Ainus hea uudis on see, et aasta vältel on hoone täituvus paranenud ning 2017. aasta Madrid Blvd tulemused peaksid olema oluliselt paremad. Kodulahe korterite ehitus ning eelmüük vastas aasta lõpu seisuga ootustele. Jätkates müügitempoga keskmiselt 6 korterit kuus, on esimene hoone välja müüdud 2018. aasta alguseks. Esimese ja suurima hoone valmimine jääb käesoleva aasta III kvartalisse. Oodatud müügitulu kokku on vähemalt 16 miljonit eurot. Lisaks oleme alustanud teise etapi hoone projekteerimisega – kokku on endise nimega Paldiski mnt 70c kinnistu arendusel viis etappi – ning sõlmisime eellepingu täiendava, detailplaneeringuta kinnistu omandamiseks 2018. aastal Kodulahe piirkonnas, et jätkata Kodulahe toote arendust ka pärast kogu Paldiski mnt 70c (2,7 ha, ca 330 korterit) kinnistu ammendumist. Hetkeseisuga oleme Kodulahe piirkonna arendajad ja müüjad vähemalt kuni aastani 2022. Iztok Parkside korterite eelmüük on ületanud ootusi. Alustasime turunduskampaaniat detsembris ning oleme tänaseks müünud „paberil“ üle 26% kogu projekti mahust. Projekti oodatud müügitulu ületab 8 miljonit eurot. Ehitamiseks läbi viidud hankes saadud pakkumised vastasid esialgsetele ootustele. Probleemiks on Sofia linna bürokraatiast tulenevad viivitused ehitusloa saamisel, millega on lükkunud edasi ka ehituslepingu sõlmimine. Kvartaliaruande kuupäeva seisuga oleme kaotanud üle 45 päeva võrreldes esialgse oodatud ajagraafikuga ning ehituse lõpp jääb seetõttu kindlasti 2018. aasta I kvartalisse. Meile näib kokkupuudetest konkurentidega, et Sofia bürokraatiasse takerduvad paljud arendajad, kuid see on väike lohutus. Samuti kasvasid neljandas kvartalis Eesti ja Bulgaaria teenindusüksuste tulud. Noorenenud hindajate ja maaklerite meeskond on hakanud näitama esimesi tulemusi, kuigi regiooniti on tulemused endiselt erinevad. Suurim väljakutse on 2017. aastal ees Tallinna linnas. Arco Vara 2017. aasta eesmärk on teenida tulu vähemalt 18 miljonit eurot ning puhaskasumina vähemalt 1,8 miljonit eurot. Selleks tuleb müüa vähemalt 120 korterit ning teenindada vahendus- ja hindamisteenustega vähemalt 6 000 klienti. 2018. aasta lõpuks soovime teenida tulu vähemalt 20 miljonit eurot ja puhaskasumina vähemalt 2 miljonit eurot, alla millise tulutaseme ei tohiks ettevõte edaspidi langeda. See on ühtlasi kogu ettevõtte ajaloos uus tase, kui me seda hoiame, ning sissejuhatus edaspidiseks. Meie eesmärk on olla kõige inimesekesksem kinnisvaraettevõte. Selle saavutamiseks kinnisvara valdkonnas on väga palju ära teha, kuid õnnestumisel on tuleviku Arco Vara tänasest mitu korda suurem. Kogu teenindusdivisjoni 2016. aasta 12 kuu müügitulu oli 3 231 tuhat eurot (2015. aasta 12 kuud: 3 254 tuhat eurot), sealhulgas kontsernisisene müügitulu 418 tuhat eurot (2015. aastal: 467 tuhat eurot). 2016. aasta IV kvartalis oli teenindusdivisjoni müügitulu 827 tuhat eurot (2015. aasta IV kvartal: 814 tuhat eurot), sealhulgas kontsernisisene müügitulu oli 136 tuhat eurot (2015. aasta IV kvartal: 100 tuhat eurot). Teenindusdivisjoni põhitegevuste (kinnisvara vahendus- ja hindamisteenused) müügitulu on 2016. aasta 12 kuuga võrreldes 2015. aasta  12 kuuga vähenenud 3%. Vähenenud mahtude üheks peapõhjuseks on asjaolu, et Läti büroolt tuli panus kontserni müügitulusse ainult 10 kuu vältel. Põhiteenuste müügitulu on kasvanud Eestis ja vähenenud Bulgaaria büroos. Bulgaaria büroo müügitulu vähenemine tuleb eelkõige vähenenud kontsernisisesest müügivahendusest, mida oli 2016. aastal võrreldes 2015. aastaga 97 tuhat eurot vähem. Muust arendusdivisjoni müügitulust moodustab suurema osa kaubandus- ja kontoripindade renditulu Madrid Blvd hoonest Sofias, mis 2016. aasta IV kvartalis oli 98 tuhat eurot ja 12 kuuga 369 tuhat eurot (2015. aasta IV kvartalis 77 tuhat eurot ja 12 kuuga 838 tuhat eurot). Renditulu on eelmise aastaga võrreldes väiksem seetõttu, et ankurrentniku leping lõppes 2015. aasta III kvartalis ja rendipinnad renoveeriti 2015. aasta IV kvartalis. Varem ühele rentnikule renditud pind on nüüdseks jagatud 7 väiksemaks kontoripinnaks. Uute rentnike otsimine endisel renditulu tasemel on osutunud keeruliseks. 2016. aasta III kvartali lõpus otsustati oluliselt alandada renditulu ootusi ning seati eesmärgiks kõigi pindade väljarentimine hiljemalt 2017. aasta II kvartalis. 2016. aasta IV kvartalis sõlmiti üks uus rendileping. Enamus kontserni omakapitalist on paigutatud arendustegevusse. Arendustegevuses on kontsern keskendunud peamiselt elukondliku kinnisvara arendusele. Elukondliku kinnisvara arendustsükkel alates algusest (maa soetamine) kuni lõpuni (lõpptoodete müük tarbijani) kestab aastaid, hõlmates planeerimismenetlust, projekteerimist, ehitust ja müüki. Omakapital investeeritakse valdavalt tsükli algusetapis (maa soetamine) eeldusel, et teatud liiki arendustoote järele tekib tulevikus nõudlus. Kuivõrd arendustoote nõudlus põhineb valdavalt prognoosidel, siis on kontserni põhiriskiks omakapitali paigutamine sellisesse arendusprojekti, mille järele tulevikus nõudlus puudub või on oodatust erinev. Kõik kontserni laenulepingud on sõlmitud eurodes ja baasintressiks on 3 või 6 kuu EURIBOR. Seega on kontsern avatud rahvusvahelistel kapitaliturgudel toimuvale. Pikaajaline intressirisk on tuletisinstrumentidega maandamata. 31.12.2016 on kontsernil intressikandvaid kohustusi summas 15,5 miljonit eurot, olles 2016. aasta 12 kuuga kasvanud 2,7 miljoni euro võrra. Lähima 12 kuu jooksul kuulub tasumisele laenukohustusi summas 9,4 miljonit eurot, sellest 9 miljonit eurot eurot moodustab Madrid projekti pangalaen Bulgaarias. Samas on kontserni raha ja raha ekvivalentide saldo 31.12.2016 seisuga 0,8 miljonit eurot (31.12.2015 seisuga: 0,7 miljonit eurot). 2016. aasta 12 kuuga tasuti intressikandvatelt kohustustelt 0,8 miljonit eurot intresse (2015. aasta 12 kuuga samuti 0,8 miljonit eurot). Kontserni intressikandvate kohustuste kaalutud keskmine intressimäär on 31.12.2016 seisuga 5,3%, see näitaja on suurenenud 0,3 protsendipunkti võrra võrreldes 2015. aasta lõpu seisuga. Laenukohutuste kaalutud keskmise intressimäära suurenemise põhjuseks on keskmisest kõrgema intressimääraga võlakohustuste võtmine 2016. aastal. ¹ - Steven Yaroslav Gorelik on fondijuhina seotud Arco Vara osalust omava kolme investeerimisfondiga (Firebird Republics Fund Ltd, Firebird Avrora Fund Ltd ja Firebird Fund L.P), mis kokku omavad 692 750 Arco Vara aktsiat (kokku 10,6% osalus).

Loading IV collaborators
Loading IV collaborators